Cardiovascular disease is the leading cause of death in western societies,with myocardial infarction as the primary assassin.Heart diseases have no geographical,gender or socio-economical boundaries.At present,cardiovascular diseases represent the most important health risks because they are responsible for more than 50% of total mortality.Among them,ischemic heart disease is the leading cause of morbidity and mortality,and according to the World Health Organization,will be the major global cause of death by the year 2020.Ischemic heart disease characterized by endothelial dysfunction,a pro-inflammatory state and often also by extensive vascular remodeling.Ang Ⅱ,the main peptide of the RAS,participates in the pathogenesis of several cardiovascular diseases.Ang Ⅱ is not only a potent vasoconstrictor which elevates arterial blood pressure,but also a powerful pro-inflammatory cytokine,chemokine and growth factor.There is accumulating evidence that Ang Ⅱ can cause target organ damage by facilitating inflammatory and growth responses through activation of NFκB,the key nuclear transcription factor in inflammatory and fibrotic diseases.Improved outcomes in clinical trials have emphasized the importance of RAS blockade in these diseases,showing beneficial organ protective effects beyond blood pressure reduction.Blockade of RAS with effective drugs will provide protection against IHD through inhibition of Ang Ⅱ production.Although ARBs and ACE inhibitors are now widely used for protection against organ damage in hypertensive and diabetic patients.